Skip to main content

PERSPECTIVE article

Front. Endocrinol.
Sec. Obesity
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1492753

Is choline kinase alpha a drug target for obesity?

Provisionally accepted
Juan Carlos Lacal Juan Carlos Lacal 1*Salam A. Ibrahim Salam A. Ibrahim 2,3*Tahl Zimmerman Tahl Zimmerman 4*
  • 1 Sols-Morreale Biomedical Research Institute (IIBM), Faculty of Medicine, Autonomous University of Madrid, Madrid, Madrid, Spain
  • 2 Instituto de Investigaciones Biomédicas, Madrid, Spain
  • 3 North Carolina Agricultural and Technical State University, Greensboro, North Carolina, United States
  • 4 High Point University, High Point, United States

The final, formatted version of the article will be published soon.

    Choline kinase alpha (ChoK) is a therapeutic target being developed for a variety of diseases, from cancer to rheumatoid arthritis and from parasites to bacterial infections. Nevertheless, the therapeutic potential of this drug target seems not exhausted and may end up as a possible solution for a larger variety of conditions.Here we present our working model for how ChoK could play a role in obesity and for how drugs being developed as therapeutics for other diseases using ChoK as a target, could be repurposed as prophylactic treatments for obesity. We also present preliminary observations in support of our model.

    Keywords: Choline, Choline Kinase, Thermogenesis, Adipogenesis, Obesity

    Received: 07 Sep 2024; Accepted: 15 Oct 2024.

    Copyright: © 2024 Lacal, Ibrahim and Zimmerman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Juan Carlos Lacal, Sols-Morreale Biomedical Research Institute (IIBM), Faculty of Medicine, Autonomous University of Madrid, Madrid, 28029, Madrid, Spain
    Salam A. Ibrahim, Instituto de Investigaciones Biomédicas, Madrid, Spain
    Tahl Zimmerman, High Point University, High Point, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.